Secukinumab shows benefit in psoriatic arthritis patients
Secukinumab may be an important new therapeutic treatment option for patients with psoriatic arthritis (PsA), according to a study published online in The New England Journal of Medicine.
Secukinumab may be an important new therapeutic treatment option for patients with psoriatic arthritis (PsA), according to a
FUTURE 1, the first multicenter, randomized, placebo-controlled phase 3 study, evaluated the efficacy and safety of secukinumab in PsA. Secukinumab is the first interleukin-17A (IL-17A) antagonist to demonstrate efficacy in a phase 3 study in patients with active PsA, a painful, debilitating condition causing inflammation of joints and skin. PsA is part of a family of long-term diseases impacting joints, known as spondyloarthritis (SpA).
Related:
“There is a high unmet need for new treatment options for patients with PsA and approximately 45% of people are dissatisfied with their treatments,” says Cathryn M. Clary, MD, head, US clinical development & medical affairs at Novartis.
In FUTURE 1, patients received an intravenous loading dose of 10 mg/kg every 2 weeks for the first 4 weeks of treatment, followed by monthly subcutaneous doses of 75 mg or 150 mg compared to placebo. The results showed secukinumab met the primary end point based on a significantly higher percentage of secukinumab patients who achieved at least a 20% reduction in the American College of Rheumatology response criteria (ACR 20) at Week 24 versus placebo. ACR is a standard tool used to assess improvement of PsA signs and symptoms such as tender and swollen joints, pain and disability. In addition, secukinumab met all pre-specified secondary end points, including improvements in skin and joint diseases and reduction of joint structural damage progression.
Results showed half of patients (50.0% and 50.5%) in both secukinumab-treated dose groups (150 mg and 75 mg; P<.001) achieved ACR 20 response compared with only 17.3% of placebo patients. Exploratory analyses showed more secukinumab-treated patients in the 150-mg and 75-mg dose groups experienced ACR 20 responses by Week 1 versus placebo (P<.001). In an additional exploratory analysis, a majority of secukinumab-treated patients achieving ACR20 responses at Week 24 also maintained the response at Week 52 with continued treatment.
Internal server error